T‐lymphocyte and glycemic status after vitamin D treatment in type 1 diabetes: A randomized controlled trial with sequential crossover

Bogdanou, Dimitra; Penna-Martinez, Marissa; Filmann, Natalie; Chung, T.L.; Morán-Auth, Y.; Wehrle, J.; Cappel, Claudia; Huenecke, Sabine; Herrmann, Eva; Koehl, Ulrike; Badenhoop, Klaus

doi:10.1002/dmrr.2865

Cited by 34 publications

(34 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The potential to modify the development of T1D was reported in a case-control study and a birth cohort follow-up study from Finland: it strongly indicated that vitamin D supplementation in infancy decreases the risk of T1D [113,114]. The therapeutic benefit of vitamin D onT1D was tested in some clinical trials [2] but only few studies examined the effect of the vitamin D SNPs in the context of vitamin D supplementation for T1D [115,116,117]. We recently performed a randomized, double-blind, placebo-controlled trial with cross-over design in which thirty-nine patients with T1D received 4000 IU/day cholecalciferol for three months followed by placebo or in reverse sequence.…”

Section: Vitamin D Pathwaysmentioning

confidence: 99%

“…Furthermore, this trial also showed an improvement of glycemic parameters under vitamin D treatment. Patients carrying the genotypes aa, TT and bb (rs7975232 ApaI , rs731236 TaqI and rs1544410 BsmI ) were capable of raising their Treg cell number [115]. A further study tested in vitro the functional role of the VDR rs10735810 ( FokI ) SNP in T-helper (CD3 + CD4 + ) from twenty patients with T1D.…”

Section: Vitamin D Pathwaysmentioning

confidence: 99%

See 1 more Smart Citation

Inherited Variation in Vitamin D Genes and Type 1 Diabetes Predisposition

Penna-Martinez

Badenhoop

2017

Genes

View full text Add to dashboard Cite

The etiology and pathophysiology of type 1 diabetes remain largely elusive with no established concepts for a causal therapy. Efforts to clarify genetic susceptibility and screening for environmental factors have identified the vitamin D system as a contributory pathway that is potentially correctable. This review aims at compiling all genetic studies addressing the vitamin D system in type 1 diabetes. Herein, association studies with case control cohorts are presented as well as family investigations with transmission tests, meta-analyses and intervention trials. Additionally, rare examples of inborn errors of vitamin D metabolism manifesting with type 1 diabetes and their immune status are discussed. We find a majority of association studies confirming a predisposing role for vitamin D receptor (VDR) polymorphisms and those of the vitamin D metabolism, particularly the CYP27B1 gene encoding the main enzyme for vitamin D activation. Associations, however, are tenuous in relation to the ethnic background of the studied populations. Intervention trials identify the specific requirements of adequate vitamin D doses to achieve vitamin D sufficiency. Preliminary evidence suggests that doses may need to be individualized in order to achieve target effects due to pharmacogenomic variation.

show abstract

Section: Vitamin D Pathwaysmentioning

confidence: 99%

Section: Vitamin D Pathwaysmentioning

confidence: 99%

Inherited Variation in Vitamin D Genes and Type 1 Diabetes Predisposition

Penna-Martinez

Badenhoop

2017

Genes

View full text Add to dashboard Cite

show abstract

“…Studies from Saudi Arabia, Egypt, Germany and Italy also indicated that vitamin D supplement therapy could improve glycemic control in children and adolescent with T1DM (14,(25)(26)(27).…”

Section: Discussionmentioning

confidence: 99%

Effect of vitamin D supplement therapy on HbA1C and IGF-1 levels in children with type 1 diabetes mellitus and vitamin D deficiency

Dehkordi

Fatemi

et al. 2018

Electron J Gen Med

View full text Add to dashboard Cite

Background: Studies indicated higher rate of vitamin D deficiency in Iranian children and also its potential role in both pathogenesis and management of Type 1 diabetes mellitus (T1DM), so we aimed to evaluate the impact of vitamin D supplement therapy on glycemic control and level of Insulin-like growth factor-I (IGF-1) in children with T1DM. Methods: In this cross-sectional study, a total of 30 children with T1DM and serum 25-hydroxyvitamin D levels lower than 29 ng/ml were enrolled. In addition to insulin therapy, the patients underwent treatment with 50,000 units of cholecalciferol (vitamin D3) once a week for a period of 12 weeks. Mean of serum vitamin D, IGF-1 and hemoglobin A1C (HbA1C), before and after treatment were compared. Results: Serum vitamin D increased significantly after 12 weeks treatment (P<0.001). Mean level of IGF-1 and HbA1c increased and decreased significantly after treatment with vitamin D supplement, respectively (P=0.01 and 0.04). There was a significant negative correlation between HbA1c and IGF-1 (r= -0.69, P<0.001) and 25(OH) D (r= -0.40, P=0.05), 12 weeks after treatment with Vitamin D3 supplement. Conclusion: Our results indicated that vitamin D treatment enhance level IGF-1 which was accompanied by decreased levels of HbA1c in patients with T1DM. So, developing a proper vitamin D treatment guideline specified in T1DM patients would result in better glycemic control and proper prevention of its related microvascular and macrovascular complication. Keywords: diabetes mellitus type 1, Glycated Hemoglobin A, insulin-like growth factor-I, vitamin D Dehkordi et al. / Effect of vitamin D supplement therapy on HbA1C and IGF-1 levels in children with type 1 diabetes mellitus and vitamin D deficiency 2 / 6

show abstract

“…Even 3000 IU/day of cholecalciferol used in the present study could barely sustain 25-(OH) D concentrations in sufficient ranges. Another study also suggests that cholecalciferol doses of 4000 IU/day are well tolerated and associated with enhancement of Tregs in T1D [28].…”

mentioning

confidence: 94%

“…Higher sun-exposure scores resulting in higher 25-(OH)D concentrations may affect the response to oral vitamin D [12]. Finally, the molecular mechanism of immunomodulation by cholecalciferol remains unexplained in our patients because we did not include the T-cell parameters as studied previously [11,13,28].…”

mentioning

confidence: 99%

Sustained serum 25-hydroxyvitamin D concentrations for one year with cholecalciferol supplementation improves glycaemic control and slows the decline of residual β cell function in children with type 1 diabetes

Panjiyar¹,

Dayal²,

Attri³

et al. 2018

pedm

View full text Add to dashboard Cite

Sustained serum 25-hydroxyvitamin D concentrations for one year with cholecalciferol supplementation improves glycaemic control and slows the decline of residual β cell function in children with type 1 diabetes Utrzymywane przez rok stężenie 25-hydroksywitaminy D w surowicy poprzez suplementację cholekalcyferolem poprawia kontrolę glikemii i spowalnia zanik resztkowej funkcji komórek β u dzieci z cukrzycą typu 1 Abstract Introduction: Studies using vitamin D for preservation of residual β-cell function (RBCF) and improvement of glycaemic control in type 1 diabetes (T1D) have shown inconsistent results. The possible causes of the discrepancies in the results are related to the dosage, type, and duration of vitamin D supplementation, C-peptide concentration at entry into the study, and the influence of glycaemic control on RBCF during supplementation. Aim of study: To evaluate the effect of cholecalciferol supplementation on RBCF and glycaemic control in children with T1D. Material and methods: Forty-two children aged 6-12 years and within 1-2 years of diagnosis of T1D received cholecalciferol 3000 IU/day for one year (Group A). Thirty patients were recruited as controls (Group B). The mean changes in stimulated C-peptide levels, HbA 1c , fasting blood glucose (FBG), mean blood glucose (MBG), and mean total daily insulin (TDI) dose from baseline to the study endpoint were calculated. Results: Children in Group A showed lower mean FBG, MBG, HbA 1c , and lesser TDI as compared to Group B at all follow-up visits. However, the differences in these parameters between the two groups reached statistical significance towards the study endpoint. Within group A, the decline in C-peptide levels from baseline to the endpoint was minor (-0.13 ±0.11, p-value = 0.16) as compared to a substantial decline in Group B (-0.41 ±0.07, p-value = 0.00). Comparison of the mean decrease in stimulated C-peptide levels from baseline to the endpoint between the two groups was also statistically significant (-0.13 ±0.11 vs. -0.41 ±0.07, p-value = 0.00). The mean decrease in FBG and MBG in Group A were greater, whereas the comparison of the mean decrease in HbA 1c between the groups reached statistical significance at the study endpoint (p-value = 0.04). The decrease in the TDI was, however, similar in the two groups (p-value = 0.10). Conclusions: Sustained serum 25-(OH)D concentrations with cholecalciferol supplementation for one year improves metabolic control and slows the decline of RBCF in children with T1D. Larger studies with longer duration and cholecalciferol dosage stratification are suggested. StreszczenieWprowadzenie: Badania z zastosowaniem witaminy D dla zachowania resztkowej funkcji komórek β (residual β-cell function -RBCF) i poprawy kontroli glikemicznej w cukrzycy typu 1 (type 1 diabetes -T1D) wykazały niespójne wyniki. Możliwe przyczyny rozbieżności w wynikach są związane z dawką, rodzajem i czasem trwania suplementacji witaminą D, stężeniem peptydu C na początku badania oraz wpływem kontroli glikemii na RBCF podczas suplement...

show abstract

T‐lymphocyte and glycemic status after vitamin D treatment in type 1 diabetes: A randomized controlled trial with sequential crossover

Abstract: A daily vitamin D dose of 4000 IU for 3 months was well tolerated and enhanced Tregs in males. Glucometabolic control improved in all. Subsequent larger trials need to address ß-cell function and genotyping for individualized vitamin D doses.

Cited by 34 publications

References 38 publications

Inherited Variation in Vitamin D Genes and Type 1 Diabetes Predisposition

Inherited Variation in Vitamin D Genes and Type 1 Diabetes Predisposition

Effect of vitamin D supplement therapy on HbA1C and IGF-1 levels in children with type 1 diabetes mellitus and vitamin D deficiency

Sustained serum 25-hydroxyvitamin D concentrations for one year with cholecalciferol supplementation improves glycaemic control and slows the decline of residual β cell function in children with type 1 diabetes

Contact Info

Product

Resources

About